search
Back to results

A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency (GSID-E)

Primary Purpose

Genetic Sucrase-Isomaltase Deficiency

Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Sucraid
Placebo
Sponsored by
QOL Medical, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Genetic Sucrase-Isomaltase Deficiency

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject is 16 years of age or older.
  2. Subject is male or female. Women of childbearing potential must be willing to use one of the following contraception methods (for at least 10 days prior to start of study drug and for 10 to 14 days after last dose of study drug): Oral contraceptive, Injectable progestogen, Implants of levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device, Sterile male partner, Double-barrier method of contraception Women of non-child bearing potential include females regardless of age with functioning ovaries and who have a current tubal ligation (Hatcher, 2004), bilateral oophorectomy, or total hysterectomy, or post-menopausal females. Note: Post-menopausal is defined as 1 year without menses with an appropriate clinical profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy).
  3. Subject has a minimum of 3 months of self-reported diarrhea (BSFS scores ≥ 5 on at least 3 days per week and ≥1 stool per day)
  4. Subject has a value in the SHMBT of at least 20 ppm for hydrogen, or 12 ppm for methane or 15 ppm above a previous breath sample for the combination of both gases.
  5. Subject reports that he/she experienced soft stools or diarrhea within the last 24 hours when contacted by the site 24 hours after completing the SHMBT.
  6. Subject is able to read, speak, and verbally understand the English language.
  7. Subject is located in the United States.
  8. Subject has access to the Internet on a daily basis.
  9. Subject has access to an acceptable Apple iPhone/iPad/iTouch or Android smartphone/tablet. The sponsor may choose to provide a smartphone in unusual cases (please contact sponsor to request loaner device when applicable)

Exclusion Criteria:

  1. Subject has recent history of functional or chronic constipation.
  2. Subject has known history of ulcerative colitis, Crohn's disease, or Celiac disease.
  3. Subject has known hypersensitivity to papain, glycerol, or yeast.
  4. Subject has received bovine serum in the last year.
  5. Subject has previous history of Sucraid use.
  6. Subject has taken any prebiotic or probiotic within 5 days prior to Visit 2 and does not agree to refrain from taking them during the study.
  7. Subject is female and is pregnant, breastfeeding, or planning to become pregnant during the study.
  8. Subject has known uncontrolled systemic disease.
  9. Subject has prior diagnosis of Type 1 or Type 2 diabetes.
  10. Subject has history of bowel resection.
  11. Subject is undergoing chemotherapy for the treatment of cancer.
  12. Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.
  13. Subject has used an investigational device or investigational drug within 30 days prior to Visit 1.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Treatment

    Placebo

    Arm Description

    Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.

    Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.

    Outcomes

    Primary Outcome Measures

    Response to Sucraid and placebo in a parallel group study based on improvement in daily stool consistency, as assessed by the BSFS using SHMBT
    Response to Sucraid and placebo based on improvement in daily stool consistency, as assessed by the Bristol Stool Form Scale (BSFS) over a 1-week treatment period in subjects with chronic diarrhea and sucrase deficiency using a sucrose hydrogen methane breath test (SHMBT).

    Secondary Outcome Measures

    Effects of Sucraid and placebo on daily assessments of Bristol Stool Form Scale
    Effects of Sucraid and placebo on daily stool frequency
    Effects of Sucraid and placebo on daily abdominal pain
    Effects of Sucraid and placebo on daily bloating severity
    The relationship between the severity of sucrase deficiency, quantified by a SHMBT
    The mean improvement in the BSFS for each treatment group.
    Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants
    Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants in comparison to the frequency in public proxy databases of broad populations.
    The number of less common sucrase-isomaltase polymorphisms in this study population.
    The allele frequency of the most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency in other databases
    Assess the allele frequency of the 38 most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency of sucrase-isomaltase genetic variants in the Exome Variant Server, the ExAC server, and other public proxy and private genetic databases.

    Full Information

    First Posted
    May 18, 2016
    Last Updated
    September 20, 2017
    Sponsor
    QOL Medical, LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02784067
    Brief Title
    A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
    Acronym
    GSID-E
    Official Title
    A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2017
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Clinical Trial Material
    Study Start Date
    May 2016 (undefined)
    Primary Completion Date
    December 2017 (Anticipated)
    Study Completion Date
    December 2017 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    QOL Medical, LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    S09A is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel study examining the efficacy and safety of a Sucraid (sacrosidase) Oral Solution in comparison to a placebo in 150-200 subjects with chronic diarrhea possibly attributable to sucrase deficiency.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Genetic Sucrase-Isomaltase Deficiency

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment
    Arm Type
    Experimental
    Arm Description
    Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
    Intervention Type
    Drug
    Intervention Name(s)
    Sucraid
    Other Intervention Name(s)
    Sacrosidase
    Intervention Description
    Study drug
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Sucraid placebo
    Primary Outcome Measure Information:
    Title
    Response to Sucraid and placebo in a parallel group study based on improvement in daily stool consistency, as assessed by the BSFS using SHMBT
    Description
    Response to Sucraid and placebo based on improvement in daily stool consistency, as assessed by the Bristol Stool Form Scale (BSFS) over a 1-week treatment period in subjects with chronic diarrhea and sucrase deficiency using a sucrose hydrogen methane breath test (SHMBT).
    Time Frame
    Up to 2 years
    Secondary Outcome Measure Information:
    Title
    Effects of Sucraid and placebo on daily assessments of Bristol Stool Form Scale
    Time Frame
    Up to 2 years
    Title
    Effects of Sucraid and placebo on daily stool frequency
    Time Frame
    Up to 2 years
    Title
    Effects of Sucraid and placebo on daily abdominal pain
    Time Frame
    Up to 2 years
    Title
    Effects of Sucraid and placebo on daily bloating severity
    Time Frame
    Up to 2 years
    Title
    The relationship between the severity of sucrase deficiency, quantified by a SHMBT
    Time Frame
    Up to 2 years
    Title
    The mean improvement in the BSFS for each treatment group.
    Time Frame
    Up to 2 years
    Title
    Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants
    Description
    Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants in comparison to the frequency in public proxy databases of broad populations.
    Time Frame
    Up to 2 years
    Title
    The number of less common sucrase-isomaltase polymorphisms in this study population.
    Time Frame
    Up to 2 years
    Title
    The allele frequency of the most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency in other databases
    Description
    Assess the allele frequency of the 38 most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency of sucrase-isomaltase genetic variants in the Exome Variant Server, the ExAC server, and other public proxy and private genetic databases.
    Time Frame
    Up to 2 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    16 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subject is 16 years of age or older. Subject is male or female. Women of childbearing potential must be willing to use one of the following contraception methods (for at least 10 days prior to start of study drug and for 10 to 14 days after last dose of study drug): Oral contraceptive, Injectable progestogen, Implants of levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device, Sterile male partner, Double-barrier method of contraception Women of non-child bearing potential include females regardless of age with functioning ovaries and who have a current tubal ligation (Hatcher, 2004), bilateral oophorectomy, or total hysterectomy, or post-menopausal females. Note: Post-menopausal is defined as 1 year without menses with an appropriate clinical profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy). Subject has a minimum of 3 months of self-reported diarrhea (BSFS scores ≥ 5 on at least 3 days per week and ≥1 stool per day) Subject has a value in the SHMBT of at least 20 ppm for hydrogen, or 12 ppm for methane or 15 ppm above a previous breath sample for the combination of both gases. Subject reports that he/she experienced soft stools or diarrhea within the last 24 hours when contacted by the site 24 hours after completing the SHMBT. Subject is able to read, speak, and verbally understand the English language. Subject is located in the United States. Subject has access to the Internet on a daily basis. Subject has access to an acceptable Apple iPhone/iPad/iTouch or Android smartphone/tablet. The sponsor may choose to provide a smartphone in unusual cases (please contact sponsor to request loaner device when applicable) Exclusion Criteria: Subject has recent history of functional or chronic constipation. Subject has known history of ulcerative colitis, Crohn's disease, or Celiac disease. Subject has known hypersensitivity to papain, glycerol, or yeast. Subject has received bovine serum in the last year. Subject has previous history of Sucraid use. Subject has taken any prebiotic or probiotic within 5 days prior to Visit 2 and does not agree to refrain from taking them during the study. Subject is female and is pregnant, breastfeeding, or planning to become pregnant during the study. Subject has known uncontrolled systemic disease. Subject has prior diagnosis of Type 1 or Type 2 diabetes. Subject has history of bowel resection. Subject is undergoing chemotherapy for the treatment of cancer. Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial. Subject has used an investigational device or investigational drug within 30 days prior to Visit 1.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    5957725
    Citation
    Arthur AB. Intestinal disaccharidase deficiency in children with coeliac disease. Arch Dis Child. 1966 Oct;41(219):519-24. doi: 10.1136/adc.41.219.519. No abstract available.
    Results Reference
    background
    PubMed Identifier
    4885929
    Citation
    Bayless TM, Christopher NL. Disaccharidase deficiency. Am J Clin Nutr. 1969 Feb;22(2):181-90. doi: 10.1093/ajcn/22.2.181.
    Results Reference
    background
    Citation
    Chumpitazi BP, Robayo-Torres CC, Tsai CM, Opekun AR, Baker SS, Nichols BL, Gilger MA, Su1110 Yield of prospective disaccharidase testing in children with recurrent abdominal pain. Gastroenterology. May 2013;144(5):S-401-S402.
    Results Reference
    background
    PubMed Identifier
    1767818
    Citation
    Cross HS, Quaroni A. Inhibition of sucrose-isomaltase expression by EGF in the human colon adenocarcinoma cells Caco-2. Am J Physiol. 1991 Dec;261(6 Pt 1):C1173-83. doi: 10.1152/ajpcell.1991.261.6.C1173.
    Results Reference
    background
    PubMed Identifier
    2759730
    Citation
    Czernichow B, Simon-Assmann P, Kedinger M, Arnold C, Parache M, Marescaux J, Zweibaum A, Haffen K. Sucrase-isomaltase expression and enterocytic ultrastructure of human colorectal tumors. Int J Cancer. 1989 Aug 15;44(2):238-44. doi: 10.1002/ijc.2910440209.
    Results Reference
    background
    PubMed Identifier
    7973215
    Citation
    DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994 Jul 15-30;13(13-14):1341-52; discussion 1353-6. doi: 10.1002/sim.4780131308.
    Results Reference
    background
    Citation
    El-Chammas K, Williams S, Miranda A. Su1254 Lactase and sucrase deficiencies in pediatric subjects with chronic abdominal pain. Gastroenterology. May 2014;146(5):S-415-S416.
    Results Reference
    background
    PubMed Identifier
    10067723
    Citation
    Gupta SK, Chong SK, Fitzgerald JF. Disaccharidase activities in children: normal values and comparison based on symptoms and histologic changes. J Pediatr Gastroenterol Nutr. 1999 Mar;28(3):246-51. doi: 10.1097/00005176-199903000-00007.
    Results Reference
    background
    Citation
    Hatcher RA, Trussell J, Stewart F, Nelson AL, Cates W, Guest F, Kowal DD, editors. Contraceptive Technology. New York: Ardent Media, 2004:226.
    Results Reference
    background
    PubMed Identifier
    1904933
    Citation
    Heitlinger LA, Rossi TM, Lee PC, Lebenthal E. Human intestinal disaccharidase activities: correlations with age, biopsy technique, and degree of villus atrophy. J Pediatr Gastroenterol Nutr. 1991 Feb;12(2):204-8.
    Results Reference
    background
    PubMed Identifier
    7055778
    Citation
    Hyams JS, Batrus CL, Grand RJ, Sallan SE. Cancer chemotherapy-induced lactose malabsorption in children. Cancer. 1982 Feb 15;49(4):646-50. doi: 10.1002/1097-0142(19820215)49:43.0.co;2-m.
    Results Reference
    background
    Citation
    Kerry KR, & Townley, R. R. Genetic aspects of intestinal sucrase-isomaltase deficiency. Australian Paediatric Journal. 1965;1:223.
    Results Reference
    background
    PubMed Identifier
    11315085
    Citation
    Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999 Dec;55(4):1286-90. doi: 10.1111/j.0006-341x.1999.01286.x.
    Results Reference
    background
    PubMed Identifier
    21936724
    Citation
    Mones RL, Yankah A, Duelfer D, Bustami R, Mercer G. Disaccharidase deficiency in pediatric patients with celiac disease and intact villi. Scand J Gastroenterol. 2011 Dec;46(12):1429-34. doi: 10.3109/00365521.2011.619276. Epub 2011 Sep 22.
    Results Reference
    background
    PubMed Identifier
    11252408
    Citation
    Murray IA, Smith JA, Coupland K, Ansell ID, Long RG. Intestinal disaccharidase deficiency without villous atrophy may represent early celiac disease. Scand J Gastroenterol. 2001 Feb;36(2):163-8. doi: 10.1080/003655201750065915.
    Results Reference
    background
    PubMed Identifier
    23103647
    Citation
    Nichols BL Jr, Adams B, Roach CM, Ma CX, Baker SS. Frequency of sucrase deficiency in mucosal biopsies. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S28-30. doi: 10.1097/01.mpg.0000421405.42386.64. No abstract available.
    Results Reference
    background
    PubMed Identifier
    497341
    Citation
    O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56.
    Results Reference
    background
    PubMed Identifier
    15290663
    Citation
    Osterlund P, Ruotsalainen T, Peuhkuri K, Korpela R, Ollus A, Ikonen M, Joensuu H, Elomaa I. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2004 Aug;2(8):696-703. doi: 10.1016/s1542-3565(04)00293-9.
    Results Reference
    background
    PubMed Identifier
    18356321
    Citation
    Quezada-Calvillo R, Sim L, Ao Z, Hamaker BR, Quaroni A, Brayer GD, Sterchi EE, Robayo-Torres CC, Rose DR, Nichols BL. Luminal starch substrate "brake" on maltase-glucoamylase activity is located within the glucoamylase subunit. J Nutr. 2008 Apr;138(4):685-92. doi: 10.1093/jn/138.4.685.
    Results Reference
    background
    Citation
    Reed, JF. (2006) AB/BA Crossover Trials - Binary Outcome. J Modern Applied Stat Methods 5 (2): 452-457.
    Results Reference
    background
    PubMed Identifier
    23103658
    Citation
    Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S7-13. doi: 10.1097/01.mpg.0000421401.57633.90. No abstract available.
    Results Reference
    background
    PubMed Identifier
    9932843
    Citation
    Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2):137-42. doi: 10.1097/00005176-199902000-00008.
    Results Reference
    background
    PubMed Identifier
    8576798
    Citation
    Treem WR. Congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1995 Jul;21(1):1-14. doi: 10.1097/00005176-199507000-00001. No abstract available.
    Results Reference
    background
    PubMed Identifier
    8405850
    Citation
    Treem WR, Ahsan N, Sullivan B, Rossi T, Holmes R, Fitzgerald J, Proujansky R, Hyams J. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. Gastroenterology. 1993 Oct;105(4):1061-8. doi: 10.1016/0016-5085(93)90950-h.
    Results Reference
    background
    PubMed Identifier
    23103650
    Citation
    Uhrich S, Wu Z, Huang JY, Scott CR. Four mutations in the SI gene are responsible for the majority of clinical symptoms of CSID. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S34-5. doi: 10.1097/01.mpg.0000421408.65257.b5. No abstract available.
    Results Reference
    background
    PubMed Identifier
    25003680
    Citation
    Wiecek S, Wos H, Radziewicz Winnicki I, Komraus M, Grzybowska Chlebowczyk U. Disaccharidase activity in children with inflammatory bowel disease. Turk J Gastroenterol. 2014 Apr;25(2):185-91. doi: 10.5152/tjg.2014.3994.
    Results Reference
    background

    Learn more about this trial

    A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency

    We'll reach out to this number within 24 hrs